JPRN-UMIN000051303尚未招募Unknown
Clinical Performance Test of Reagent for BRAF Gene Mutation Detection in Solid Tumors - Clinical Performance Test of Reagent for BRAF Gene Mutation Detection in Solid Tumors
ational Cancer Center Hospital East0 个研究点目标入组 138 人开始时间: 2023年6月12日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Cases in which the patient has indicated his/her intention to refuse the use of the sample/information for this study from the start of this study to the start of the analysis. 2.Cases in which the patient is a minor.
研究者
相似试验
已完成
1 期
EVICT: The erlotinib and vemurafenib in combination trial.A Phase I/II Trial of the combination of BRAF and EGFR inhibition in BRAF V600E mutant colorectal, advanced or metastatic lung adenocarcinoma and other cancers.Colorectal Cancer (metastatic)Lung Cancer (metastatic)Cancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - Lung - Non small cellACTRN12614000486628Peter MacCallum Cancer Centre46
已完成
2 期
BRF113928: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer10029107non-small cell lung cancerlung cancerNL-OMON47910ovartis20
尚未招募
不适用
Observational Study of BRAF Inhibitor Combination Therapy for BRAF mutant Metastatic Colorectal Cancer including Biomarker Research: BEETS trial(JACCRO CC-18)Colorectal CancerJPRN-UMIN000045530JACCRO200
进行中（未招募）
1 期
A study to test a new drug for treating non-small cell lung cancerAdvanced non-small cell lung cancer and BRAF mutationsMedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001161-41-ITGlaxoSmithKline Research and Development Limited100
进行中（未招募）
1 期
A study to test a new drug for treating non-small cell lung cancerEUCTR2011-001161-41-GBovartis Pharma Services AG166